Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors

Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors
Gordon Fehr to retire after 16 years of leadership on the board

AMBRIDGE, Mass., June 15, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the election of John M. Dineen to its Board of Directors. Dineen, the former Chief Executive Officer of GE Healthcare, currently serves as an Operating Advisor to Clayton, Dublier & Rice, LLC.

"John is one of the healthcare industry's top operating executives having led the global growth and exceptional performance of GE Healthcare," said Gary Crocker, Chairman of the Board of Merrimack. "He brings a passion for the industry, a deep knowledge of global healthcare, pharmaceuticals and diagnostics, and a distinguished career in commercial and operational leadership that will be invaluable for Merrimack as we transition to a commercial company."

Dineen led several of the top businesses during his career at GE. Most recently, he served as the CEO of GE Healthcare, an $18 billion global healthcare business.  Previously, he was the CEO of GE Transportation, President of GE Plastics, General Manager of GE's Power Equipment business and General Manager of GE's Appliances, Microwave and Air-Conditioning businesses.  He also served in various assignments in Corporate Finance, including Manager of Finance for GE Asia in Hong Kong. Dineen is a graduate of the University of Vermont, where he earned bachelor's degrees in biological sciences and computer science. 

"I am pleased to be joining the team at Merrimack to help guide the development of a fully integrated cancer company," said Dineen. "The company's pioneering discovery platform and the robust pipeline of novel therapeutic and diagnostics provide a strong foundation for an exciting future of clinical and commercial growth."

Merrimack also announced today the retirement of Gordon Fehr from its Board of Directors. Fehr is a former Chairman and President of Pfizer Canada and has served as a member of Merrimack's board since 1999.

"We owe tremendous gratitude to Gordon for his time and service on our board. His dedication to building and developing Merrimack from its founding to a commercial organization has been instrumental to our success. We thank him immensely for his commitment to our people, our science and to cancer care," said Bob Mulroy, CEO of Merrimack.

Dineen is joining Board members Gary Crocker, Board Chairman and President of Crocker Ventures; Vivian Lee, Ph.D., M.D., Senior Vice President for Health Sciences at the University of Utah, Dean of the University's School of Medicine, and CEO of University of Utah Health Care; John Mendelsohn, M.D., co-director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy at MD Anderson and former President of MD Anderson; Ulrik B. Nielsen, Ph.D., co-founder and former Chief Scientific Officer of Merrimack and CEO of Torque Inc.; Michael Porter, Ph.D., Bishop William Lawrence University Professor at Harvard Business School; James Quigley, former CEO of Deloitte Touche Tohmatsu, Limited (the Deloitte Global Network); Russell Ray, Senior Advisor to HLM Venture Partners; and Robert Mulroy, President and CEO of Merrimack.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has submitted a New Drug Application for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. For more information, please visit Merrimack's website at www.merrimackpharma.com or connect on Twitter at @MerrimackPharma. 

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT: 
Media Contact:
Debbie Tseng
Merrimack
617-441-7659
[email protected]

Investor Contact:
Geoffrey Grande, CFA
Merrimack
617-441-7602
[email protected]

Photo - http://photos.prnewswire.com/prnh/20150615/223104

SOURCE Merrimack Pharmaceuticals, Inc.

RELATED LINKS
http://www.merrimackpharma.com

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.